← Back to all stacks

Female Libido & Sexual Function Stack

Category
Sexual Health
Purpose
Sexual Desire & Arousal in Women
Peptides
PT-141BPC-157

Overview

PT-141 (Bremelanotide) is the only FDA-approved non-hormonal treatment for hypoactive sexual desire disorder in premenopausal women. BPC-157 is added for its supporting effects on vascular health and its modulation of the dopaminergic system, which may enhance the central arousal effects of PT-141.

The main peptide is an FDA-approved treatment for low sexual desire in women, and the second peptide is added to support blood flow and potentially strengthen that effect.

Compounds in this stack

PT-141 FDA Approved

An FDA-approved treatment that restores sexual desire by acting on the brain, not the blood vessels.

BPC-157 Research

A widely studied 'healing peptide' derived from stomach protein. Popular for helping the body repair muscle, tendon, and gut tissue faster.

Preferred Peptide Vendors →

⚠️ This page describes a combination of compounds that are, with few exceptions, not approved by the FDA for any use. It records protocols described in research and community sources. It is not a recommendation, not a prescription, and not medical advice. Combining compounds multiplies the unknowns rather than adding them. Do not act on anything here without a qualified healthcare professional who knows your history.